Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nedaplatin + pemetrexed
- Development stage
- Phase 3
- Lead developer
- Nichi-Iko Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of nedaplatin (a second-generation platinum drug) and pemetrexed (an antifolate antineoplastic agent). This combination is primarily used for the treatment of advanced lung adenocarcinoma, showing high efficacy and good patient tolerance. Nedaplatin exhibits similar therapeutic effects to cisplatin but has 10-fold greater water solubility and lower nephrotoxicity and gastrointestinal toxicity. Its major dose-limiting toxicity is bone marrow suppression. Pemetrexed is an antifolate antineoplastic agent that works by disrupting folate-dependent metabolic processes essential for cell replication.
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on nedaplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nedaplatin + pemetrexed.